09/890442

| "Express Mail" mailing label number | EL 392 682 368 US |
|-------------------------------------|-------------------|
| | |
| | |

Date of Deposit: July 26, 2001

Our Case No.: 9793/73

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Johann Karl et al.

Serial No.: New Application

Filing Date: Herewith

For: Assay for the Detection of N-

Terminal proBNP

Examiner: To be assigned

Group Art Unit No.: To be assigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents A1-A13 listed on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner. A copy of the International Search Report is also enclosed.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely

JC17 PCT/PTO 2.6 JUL 2001

filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this material, the Commissioner is hereby authorized to deduct the fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Jeffery M. Duncan

Registration No. 31,609 Attorney for Applicants

BRINKS HOFER GILSON & LIONE P.O. Box 10395 Chicago, IL 60610 (312) 321-4200

1C17 Rec'd PCT/PTO 26 JUL 2001 09/890442

| FORM PTO-1449 | SERIAL NO. | CASE NO. |
|--------------------------------------|----------------------------------|----------------|
| | New Application | 9793/73 |
| LIST OF PATENTS AND PUBLICATIONS FOR | FILING DATE | GROUP ART UNIT |
| APPLICANT'S INFORMATION DISCLOSURE | Herewith | To be assigned |
| STATEMENT | | |
| (use several sheets if necessary) | APPLICANT(S): Johann Karl et al. | |

| REFERENCE | DESIG | NATION | U.S. PATEN | T DOCUMENTS | | |
|-----------|--------------|----------|------------|-------------|----------|--------|
| EXAMINER | | DOCUMENT | | 1 | CLASS/ | FILING |
| INITIAL | | NUMBER | DATE | NAME | SUBCLASS | DATE |

FOREIGN PATENT DOCUMENTS

| EXAMINER | | DOCUMENT | | | CLASS/ | TRANS | LATION |
|----------|----|--------------|----------|---------|----------|-------|--------|
| INITIAL | | NUMBER | DATE | COUNTRY | SUBCLASS | YES | NO |
| | A1 | 0 186 799 A1 | 07/09/86 | EPO | | | Х |
| | A2 | 0 542 255 A1 | 05/19/93 | EPO | | | Χ |
| | A3 | WO 93/24531 | 12/09/93 | WIPO | | | Х |

| EXAMINER | | | | | | |
|----------|--|--|--|--|--|--|
| INITIAL | OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| | A4 | P. J. Hunt et al. "Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment," Clinical Endocrinology (1997), Vol. 47, pp. 287-296. | | | | |
| | A5 | Sreedevi Daggubati et al. "Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators," Cardiovascular Research, Vol. 36 (1997), pp. 246-255. | | | | |
| | A6 | G. Köhler et al. "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, Vol. 256 (1975), pp. 495-497. | | | | |
| | A7 | Martin G. Buckley et al. "Prolonged stability of brain natriuretic peptide: importance for non-invasive assessment of cardiac function in clinical practice," Clinical Science (1998), Vol. 95, pp. 235-239. | | | | |
| | A8 | John G. F. Cleland et al. "Stability of plasma concentrations of N and C terminal atrial natriuretic peptides at room temperature," Heart (1996), Vol. 75, pp. 410-413. | | | | |
| | A9 | Tetsuji Sudoh et al. "A new natriuretic peptide in porcine brain," Nature, Vol. 332 (1988), pp. 78-81. | | | | |
| | A10 | K. Masuta et al. "Assessment of human brain natriuretic peptide stability in clinical samples," Clinical Chemistry, Vol. 44, No. 6, Supplement, Abstract No. 563 (1998), page A130. | | | | |
| | A11 | Tetsuo Tsuji et al. "Stabilization of Human Brain Natriuretic Peptide in Blood Samples," Clinical Chemistry, Vol. 40, No. 4 (1994), pp. 672-673. | | | | |
| | A12 | P. J. Hunt et al. "The Amino-Terminal Portion of Pro-Brain Natriuretic Peptide (Pro-BNP) Circulates in Human Plasma," Biochemical and Biophysical Research Communications, Vol. 214, No. 3 (1995), pp. 1175-1183. | | | | |
| | A13 | P. J. Hunt et al. "The Role of the Circulation in Processing pro-Brain Natriuretic Peptide (proBNP) to Amino-Terminal BNP and BNP-32," Peptides, Vol. 18, No. 10, pp. 1475-1481. | | | | |

| EXAMINER | DATE CONSIDERED |
|-----------|-----------------|
| EVAIMINEL | DATE CONSIDERED |
| | |
| | _ |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Rev. Dec.-99